Martí-Carreras Joan, Carrasco Marina, Gómez-Ponce Marcel, Noguera-Julián Marc, Fisa Roser, Riera Cristina, Alcover Maria Magdalena, Roura Xavier, Ferrer Lluís, Francino Olga
Nano1Health S.L. (N1H), Edifici EUREKA, Parc de Recerca UAB, Bellaterra, 08193 Barcelona, Spain.
Laboratori de Parasitologia, Departament de Biologia Sanitat i Mediambient, Facultat de Farmàcia I Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.
Microorganisms. 2022 Nov 14;10(11):2256. doi: 10.3390/microorganisms10112256.
The emergence of drug-resistant strains of the parasite infecting dogs and humans represents an increasing threat. genomes are complex and unstable with extensive structural variations, ranging from aneuploidies to multiple copy number variations (CNVs). These CNVs have recently been validated as biomarkers of concerning virulence, tissue tropism, and drug resistance. As a proof-of-concept to develop a novel diagnosis platform (LeishGenApp), four samples from humans and dogs were nanopore sequenced. Samples were epidemiologically typed within the Mediterranean group, identifying members of the and subgroups, using the conserved region (CR) of the maxicircle kinetoplast. Aneuploidies were frequent and heterogenous between samples, yet only chromosome 31 tetrasomy was common between all the samples. A high frequency of aneuploidies was observed for samples with long passage history (MHOM/TN/80/IPT-1), whereas fewer were detected for samples maintained in vivo (MCRI/ES/2006/CATB033). Twenty-two genes were studied to generate a genetic pharmacoresistance profile against miltefosine, allopurinol, trivalent antimonials, amphotericin, and paromomycin. MHOM/TN/80/IPT-1 and MCRI/ES/2006/CATB033 displayed a genetic profile with potential resistance against miltefosine and allopurinol. Meanwhile, MHOM/ES/2016/CATB101 and LCAN/ES/2020/CATB102 were identified as potentially resistant against paromomycin. All four samples displayed a genetic profile for resistance against trivalent antimonials. Overall, this proof-of-concept revealed the potential of nanopore sequencing and LeishGenApp for the determination of epidemiological, drug resistance, and pathogenicity biomarkers in .
感染犬类和人类的寄生虫耐药菌株的出现构成了日益严重的威胁。其基因组复杂且不稳定,存在广泛的结构变异,从非整倍体到多种拷贝数变异(CNV)。这些CNV最近已被确认为有关毒力、组织嗜性和耐药性的生物标志物。作为开发新型诊断平台(LeishGenApp)的概念验证,对来自人类和犬类的四个样本进行了纳米孔测序。在地中海组内对样本进行流行病学分型,利用大环状动质体的保守区域(CR)鉴定和亚组的成员。样本间非整倍体频繁且异质,但所有样本中仅31号染色体四体性常见。对于传代历史较长的样本(MHOM/TN/80/IPT-1),观察到非整倍体频率较高,而在体内保存的样本(MCRI/ES/2006/CATB033)中检测到的较少。研究了22个基因以生成针对米替福新、别嘌呤醇、三价锑剂、两性霉素和巴龙霉素的遗传耐药谱。MHOM/TN/80/IPT-1和MCRI/ES/2006/CATB033显示出对米替福新和别嘌呤醇具有潜在耐药性的遗传谱。同时,MHOM/ES/2016/CATB101和LCAN/ES/2020/CATB102被鉴定为对巴龙霉素具有潜在耐药性。所有四个样本均显示出对三价锑剂耐药的遗传谱。总体而言,这一概念验证揭示了纳米孔测序和LeishGenApp在确定流行病学、耐药性和致病性生物标志物方面的潜力。